佰泽医疗(02609.HK)2025 中期业绩亮眼：经调整净利润大增 72.8% 肿瘤全周期服务优势持续凸显

Core Viewpoint - Baize Medical Group (stock code: 02609.HK) has demonstrated strong internal growth resilience and sustainable development potential amid a complex and changing market environment in the healthcare industry, as evidenced by its mid-year performance for 2025 [1] Financial Performance - For the first half of 2025, the company reported revenue of approximately RMB 575 million, reflecting a steady growth of 0.7% compared to the same period in 2024 [1] - The gross profit reached approximately RMB 106 million, representing an increase of 8.3% year-on-year [1] - Adjusted net profit (excluding listing expenses) was approximately RMB 9.4 million, showing a significant year-on-year growth of 72.8% [1]